Active Control of Prostatic Cancer With Criteria of Latence — SURACAP  

Prostate Cancer Clinical Trial

Official title: Active Control of Prostatic Cancer With Criteria of Latence. Impact on Specific 10 Years Survival.

Status Terminated

Clinical Trial Summary

This study concern a prospective cohort pf patients with latent prostate cancer. We study the specific survival at 10 years of patients who accept an active control.Patients inclusion are realized in 2 stages:

• patient with inclusion criteria (PSA < 10 ng/ml, clinical stage T1c or T2a, Gleason < or = 6) are registered if they accept a second prostate biopsy in a 3 months delay

• after analyse of second biopsy in central laboratory and confirmation of latent prostate biopsy, patients are included if they accept active control Included patients will have 1 biopsy by years the first two years and then 1 biopsy each 2 years during 8 years.

If progression of cancer happens during the 10 years control, active control will be stopped and patient will be treated by surgery and chemotherapy.

Clinical Trial Description

This study concern the active control during 10 years of patient with latent prostate cancer who accept not be treated immediately. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT00921258
• Study type: Observational
• Source: Clinique Mutualiste Chirurgicale de la Loire
• Status: Terminated
• Phase: N/A
• Start date: December 2007
• Completion date: December 2013